Chronic urticaria
diseaseOn this page
Summary
Chronic urticaria (MONDO:0850230) is a disease and 48 clinical trials. Top therapeutic interventions include levocetirizine, omalizumab, and clemastine. A subtype of urticaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 48
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | chronic urticaria |
| Mondo ID | MONDO:0850230 |
| DOID | DOID:0080747 |
| ICD-11 | 901000137 |
| UMLS | C0263338 |
| MedGen | 537829 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of urticaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria › chronic urticaria
Related subtypes (13): allergic urticaria, physical urticaria, Melkersson-Rosenthal syndrome, pruritic urticarial papules and plaques of pregnancy, urticaria, aquagenic, urticaria, familial localized heat, angioedema, drug rash with eosinophilia and systemic symptoms, cutaneous mastocytosis, cold urticaria, autoimmune urticaria, papular urticaria, idiopathic urticaria
Subtypes (1): chronic inducible urticaria
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 48.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 23 |
| PHASE2 | 9 |
| PHASE3 | 8 |
| PHASE4 | 4 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01250652 | PHASE4 | COMPLETED | Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses |
| NCT01586091 | PHASE4 | COMPLETED | Safety Study of Levocetirizine and Fexofenadine |
| NCT01701583 | PHASE4 | COMPLETED | Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria |
| NCT03111628 | PHASE4 | COMPLETED | Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) |
| NCT00598611 | PHASE3 | COMPLETED | Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) |
| NCT00619801 | PHASE3 | COMPLETED | Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin |
| NCT00628108 | PHASE3 | COMPLETED | Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months |
| NCT01715740 | PHASE3 | COMPLETED | Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria |
| NCT01803763 | PHASE2/PHASE3 | COMPLETED | Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients |
| NCT01960283 | PHASE3 | COMPLETED | Methotrexate in the Treatment of Chronic Idiopathic Urticaria |
| NCT02213367 | PHASE3 | COMPLETED | Bilastine Updosing in Chronic Spontaneous Urticaria |
| NCT02358265 | PHASE3 | TERMINATED | Chronic Urticaria - Long Term Assessment of Effects of Rupatadine |
| NCT04976192 | PHASE3 | COMPLETED | Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria |
| NCT06736262 | PHASE2 | ACTIVE_NOT_RECRUITING | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials |
| NCT06816784 | PHASE2 | NOT_YET_RECRUITING | Treatment Options for Chronic Urticaria |
| NCT06927999 | PHASE2 | RECRUITING | An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria |
| NCT00481676 | PHASE2 | COMPLETED | Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria |
| NCT01081574 | PHASE1/PHASE2 | COMPLETED | Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU) |
| NCT01170949 | PHASE2 | TERMINATED | Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria |
| NCT01713725 | PHASE2 | COMPLETED | Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria |
| NCT03436797 | PHASE2 | COMPLETED | A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria |
| NCT04967092 | PHASE2 | UNKNOWN | Modified Xiao-Feng Powder for Chronic Urticaria |
| NCT06268470 | PHASE2 | UNKNOWN | Antiplatelet Therapy in Chronic Urticaria |
| NCT03632291 | PHASE1 | COMPLETED | Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients |
| NCT05461456 | PHASE1 | COMPLETED | Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% |
| NCT00737451 | Not specified | COMPLETED | Association of Thyroid Autoimmunity and Chronic Urticaria |
| NCT01047137 | Not specified | WITHDRAWN | Response of Urticaria to Stress Intervention |
| NCT01073852 | Not specified | WITHDRAWN | Hydroxychloroquine Efficacy in Chronic Urticaria |
| NCT01111136 | Not specified | COMPLETED | Stress Intervention for Chronic Urticaria |
| NCT01284426 | Not specified | COMPLETED | Natural History of Chronic Urticaria |
| NCT01425593 | Not specified | UNKNOWN | T Cell Function in Chronic Idiopathic Urticaria |
| NCT01610128 | Not specified | COMPLETED | Development of an Urticaria Control Test |
| NCT01614834 | Not specified | COMPLETED | Validation of an Urticaria Control Test |
| NCT02000648 | Not specified | COMPLETED | Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in Thailand |
| NCT02047136 | Not specified | TERMINATED | Dietary Treatment for Chronic Urticaria |
| NCT02285023 | Not specified | COMPLETED | The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire |
| NCT02285049 | Not specified | COMPLETED | Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test |
| NCT02435238 | Not specified | COMPLETED | AWARE - Chronic Urticaria |
| NCT02626221 | Not specified | COMPLETED | A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan) |
| NCT03151902 | Not specified | COMPLETED | Detection of Viral Particels in Urticaria Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LEVOCETIRIZINE | 4 | 5 |
| OMALIZUMAB | 4 | 5 |
| CLEMASTINE | 4 | 3 |
| FEXOFENADINE | 4 | 3 |
| BILASTINE | 4 | 2 |
| DESLORATADINE | 4 | 2 |
| DIPYRIDAMOLE | 4 | 1 |
| LORATADINE | 4 | 1 |
| MILTEFOSINE | 4 | 1 |
| RUPATADINE | 4 | 1 |
| LIRENTELIMAB | 3 | 1 |
| BRIQUILIMAB | 2 | 1 |